Black Diamond Therapeutics, Inc. (BDTX)

BDTX Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Selling, General & Admin	15.64	24.52	27.11	28.39	30.04	21.36
Research & Development	39.56	51.31	59.35	64.44	96.83	48.21
Operating Expenses	55.2	75.84	86.46	92.83	126.87	69.57
Operating Income	14.8	-75.84	-86.46	-92.83	-126.87	-69.57
Interest Expense	-	-	-	-	-	-0
Interest & Investment Income	3.44	2.18	1.92	2.03	3.46	4.04
Earnings From Equity Investments	-	-	-	-2.25	-	-
Currency Exchange Gain (Loss)	-	-	-	-	-0	0
Other Non Operating Income (Expenses)	2.42	3.14	0.92	0.18	-	-
EBT Excluding Unusual Items	20.66	-70.51	-83.62	-92.87	-123.41	-65.53
Merger & Restructuring Charges	-2.95	-2.95	-	-	-	-
Gain (Loss) on Sale of Investments	3.78	3.78	1.17	-0.54	-2.19	-1.73
Gain (Loss) on Sale of Assets	-	-	-	2.23	-	-
Pretax Income	21.5	-69.68	-82.44	-91.17	-125.6	-67.25
Net Income	21.5	-69.68	-82.44	-91.17	-125.6	-67.25
Net Income to Common	21.5	-69.68	-82.44	-91.17	-125.6	-67.25
Shares Outstanding (Basic)	57	55	44	36	36	33
Shares Outstanding (Diluted)	57	55	44	36	36	33
Shares Change (YoY)	6.44%	25.19%	21.00%	0.38%	9.97%	1485.31%
EPS (Basic)	0.38	-1.27	-1.88	-2.51	-3.47	-2.04
EPS (Diluted)	0.38	-1.27	-1.88	-2.51	-3.47	-2.05
Free Cash Flow	21.35	-62.3	-66.75	-85.27	-102.86	-52.29
Free Cash Flow Per Share	0.37	-1.13	-1.52	-2.35	-2.84	-1.59
EBITDA	15.15	-75.49	-86.02	-92.32	-126.67	-69.52
D&A For EBITDA	0.34	0.34	0.44	0.51	0.21	0.05
EBIT	14.8	-75.84	-86.46	-92.83	-126.87	-69.57

Updated Nov 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q